Skip to main content
PMC home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1995 Dec;85(12):1706–1709. doi: 10.2105/ajph.85.12.1706

The reporting sensitivities of two passive surveillance systems for vaccine adverse events.

S Rosenthal 1, R Chen 1
PMCID: PMC1615747  PMID: 7503351

Abstract

To evaluate reporting sensitivities for vaccine adverse events, reporting rates were estimated by dividing the number of events reported to the Monitoring System for Adverse Events Following Immunization and the Vaccine Adverse Event Reporting System in a given period by the number of doses administered or distributed during the same period. Reporting sensitivity was calculated as the ratio of the rates at which events were reported to each passive surveillance system (numerator) and occurred in controlled studies (denominator). Reporting sensitivities were generally better in the public sector than in the private sector. The significant underreporting of known outcomes, together with the nonspecific nature of most adverse event reports, highlights the limitations of passive surveillance systems in assessing the incidence of vaccine adverse events.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chen R. T., Haber P., Mullen J. R. Surveillance of the safety of simultaneous administration of vaccines. The Centers for Disease Control and Prevention experience. Ann N Y Acad Sci. 1995 May 31;754:309–320. doi: 10.1111/j.1749-6632.1995.tb44464.x. [DOI] [PubMed] [Google Scholar]
  2. Chen R. T., Rastogi S. C., Mullen J. R., Hayes S. W., Cochi S. L., Donlon J. A., Wassilak S. G. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994 May;12(6):542–550. doi: 10.1016/0264-410x(94)90315-8. [DOI] [PubMed] [Google Scholar]
  3. Cochi S. L., Edmonds L. E., Dyer K., Greaves W. L., Marks J. S., Rovira E. Z., Preblud S. R., Orenstein W. A. Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination. Am J Epidemiol. 1989 Feb;129(2):349–361. doi: 10.1093/oxfordjournals.aje.a115138. [DOI] [PubMed] [Google Scholar]
  4. Cody C. L., Baraff L. J., Cherry J. D., Marcy S. M., Manclark C. R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981 Nov;68(5):650–660. [PubMed] [Google Scholar]
  5. Deforest A., Long S. S., Lischner H. W., Girone J. A., Clark J. L., Srinivasan R., Maguire T. G., Diamond S. A., Schiller R. P., Rothstein E. P. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics. 1988 Feb;81(2):237–246. [PubMed] [Google Scholar]
  6. Fletcher A. P. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991 Jun;84(6):341–344. doi: 10.1177/014107689108400612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Griffin M. R., Ray W. A., Mortimer E. A., Fenichel G. M., Schaffner W. Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991 Nov;88(5):881–885. [PubMed] [Google Scholar]
  8. Nieminen U., Peltola H., Syrjälä M. T., Mäkipernaa A., Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993 Mar;82(3):267–270. doi: 10.1111/j.1651-2227.1993.tb12657.x. [DOI] [PubMed] [Google Scholar]
  9. Pollock T. M., Miller E., Mortimer J. Y., Smith G. Post-vaccination symptoms following DTP and DT vaccination. Dev Biol Stand. 1985;61:407–410. [PubMed] [Google Scholar]
  10. Pollock T. M., Morris J. A 7-year survey of disorders attributed to vaccination in North West Thames region. Lancet. 1983 Apr 2;1(8327):753–757. doi: 10.1016/s0140-6736(83)92037-8. [DOI] [PubMed] [Google Scholar]
  11. Scott H. D., Thacher-Renshaw A., Rosenbaum S. E., Waters W. J., Jr, Green M., Andrews L. G., Faich G. A. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA. 1990 Apr 4;263(13):1785–1788. [PubMed] [Google Scholar]
  12. Sills J. M., Tanner L. A., Milstien J. B. Food and Drug Administration monitoring of adverse drug reactions. Am J Hosp Pharm. 1986 Nov;43(11):2764–2770. [PubMed] [Google Scholar]
  13. Stetler H. C., Mullen J. R., Brennan J. P., Livengood J. R., Orenstein W. A., Hinman A. R. Monitoring system for adverse events following immunization. Vaccine. 1987 Sep;5(3):169–174. doi: 10.1016/0264-410x(87)90094-6. [DOI] [PubMed] [Google Scholar]
  14. Stetler H. C., Orenstein W. A., Bart K. J., Brink E. W., Brennan J. P., Hinman A. R. History of convulsions and use of pertussis vaccine. J Pediatr. 1985 Aug;107(2):175–179. doi: 10.1016/s0022-3476(85)80120-7. [DOI] [PubMed] [Google Scholar]
  15. Strebel P. M., Sutter R. W., Cochi S. L., Biellik R. J., Brink E. W., Kew O. M., Pallansch M. A., Orenstein W. A., Hinman A. R. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992 Feb;14(2):568–579. doi: 10.1093/clinids/14.2.568. [DOI] [PubMed] [Google Scholar]
  16. Sutter R. W., Cochi S. L., Brink E. W., Sirotkin B. I. Assessment of vital statistics and surveillance data for monitoring tetanus mortality, United States, 1979-1984. Am J Epidemiol. 1990 Jan;131(1):132–142. doi: 10.1093/oxfordjournals.aje.a115466. [DOI] [PubMed] [Google Scholar]
  17. Sutter R. W., Cochi S. L. Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting. JAMA. 1992 Jan 15;267(3):386–391. [PubMed] [Google Scholar]
  18. Walker A. M., Jick H., Perera D. R., Thompson R. S., Knauss T. A. Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health. 1987 Aug;77(8):945–951. doi: 10.2105/ajph.77.8.945. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES